Oxford Nanopore Secures $41M for Development of GridIon Platform

The funding will allow the company to validate its technology, including "interacting with key users who represent the spectrum of the particular application area, whether it's protein analysis or sequencing, and then ultimately, through commercialization," said CEO Gordon Sanghera.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.